Question Description
Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? for GMAT 2024 is part of GMAT preparation. The Question and answers have been prepared according to the GMAT exam syllabus. Information about Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? covers all topics & solutions for GMAT 2024 Exam. Find important definitions, questions, meanings, examples, exercises and tests below for Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer?.

Solutions for Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? in English & in Hindi are available as part of our courses for GMAT. Download more important topics, notes, lectures and mock test series for GMAT Exam by signing up for free.

Here you can find the meaning of Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? defined & explained in the simplest way possible. Besides giving the explanation of Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer?, a detailed solution for Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? has been provided alongside types of Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? theory, EduRev gives you an ample number of questions to practice Symptoms of Parkinson’s Disease, such as tremors, are thought to be caused by low dopamine levels in the brain.Current treatments of Parkinson’s disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died.Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson’s patients.Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alphasynuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell.Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients.Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson’s patients, but other causes may exist. Most scientists involved with Parkinson’s research do agree, however, that such promising early results provide a basis for further testing.Q.One function of the third paragraph of the passage is toa)highlight the many similarities between yeast cells and mammalian nerve cellsb)explain in detail the methods used to conduct a genetic screen in yeast cellsc)further explain the roles of variouscellular components of yeast cellsd)identify the genes in yeast cells and mammalian nerve cells that work to reverse the toxic levels of alphasynucleine)clarify the relevance of genetic testing in yeast cells to the search for a new treatment for Parkinson’s diseaseCorrect answer is option 'E'. Can you explain this answer? tests, examples and also practice GMAT tests.